Clearstead Advisors’s Solid Biosciences SLDB Stock Holding History

Clearstead Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$44	–	3230
2025 Q2	$44	Buy	+9	New	+$32	﹤0.01%	2680

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clearstead Advisors's SLDB Position: Q3 2025 in Review

Clearstead Advisors sold out of Solid Biosciences (SLDB) in Q3 2025, closing a stake of 9 shares — an estimated $44 sold.

Clearstead Advisors first reported a position in SLDB in Q2 2025 and held it in 1 quarter. The position peaked at $44 in Q2 2025. 127 funds tracked by Wall St. Rank hold SLDB as of Q3 2025.

Clearstead Advisors reported no remaining Solid Biosciences position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 9 Solid Biosciences shares in Q3 2025, an estimated $44.
Clearstead Advisors first reported a position in Solid Biosciences in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's Solid Biosciences position peaked at $44 in Q2 2025.
127 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.